Parenteral methotrexate in psoriasis. A report on the efficacy and toxicity of long-term intermittent treatment.

Parenteral methotrexate in psoriasis. A report on the efficacy and toxicity of long-term intermittent treatment. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Parenteral methotrexate in psoriasis. A report on the efficacy and toxicity of long-term intermittent treatment. Abstract Text:

Parenteral methotrexate in psoriasis. A report on the efficacy and toxicity of long-term intermittent treatment. Publishing Authors By Initials

For similar natural sciences: time: time factors research abstracts see: natural sciences: time: time factors research

PUBMED ID PMID:

MEDLINE DATE:

Parenteral methotrexate in psoriasis. A report on the efficacy and toxicity of long-term intermittent treatment. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Archives of dermatology

VOLUME: 100

Page Numbers: 655-68

Journal Abbreviation: Arch Dermatol

ISSN: 0003-987X

DAY: 17

MONTH: Dec

YEAR: 1969

Parenteral methotrexate in psoriasis. A report on the efficacy and toxicity of long-term intermittent treatment. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 372433

Parenteral methotrexate in psoriasis. A report on the efficacy and toxicity of long-term intermittent treatment. Keywords Mesh Terms:

KEYWORDS: Time Factors

MESH TERMS: chemically induced

Chemical & Substance for Abstract: Parenteral methotrexate in psoriasis. A report on the efficacy and toxicity of long-term intermittent treatment. Information

Substance Name: Alkaline Phosphatase

Registry Number: EC 3.1.3.1

Grant and Affiliation Information for Parenteral methotrexate in psoriasis. A report on the efficacy and toxicity of long-term intermittent treatment.

AFFILIATION:

Country: UNITED STATES

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Arch Dermatol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Parenteral methotrexate in psoriasis A report on the efficacy and toxicity of long-term intermittent treatment Related Publications

• A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance.
• Absorption of leucovorin (NSC-3590) from a "mouthwash".
• Asymmetries of poverty: why global burden of disease valuations underestimate the burden of neglected tropical diseases.
• Chemotherapeutic approaches to advanced carcinoma of the larynx.
• Combination chemotherapy with cyclophosphamide (NSC-26271), cytosine arabinoside (NSC-63878), and methotrexate (NSC-740) in advanced solid tumors.
• Evaluation of dose-intense Ifosfamide, with and without edatrexate, in adults with sarcoma.
• Failure of leucovorin "rescue" in methotrexate treatment of psoriasis.
• Head and neck cancer. 3. Toxicity of 24-hour infusions of methotrexate (NSC-740) and protection by leucovorin (NSC-3590) in patients with epidermoid carcinomas.
• Implantable pump for long-term chemotherapy administration via the hepatic artery: has it fulfilled its promise?
• In vitro reconstructed normal human epidermis expresses differentiation-related proteoglycans.
• Methotrexate (NSC-740) in squamous cell carcinoma of the head and neck. II. Intermittent intravenous therapy.
• MiRSNPs or MiR-polymorphisms, new players in microRNA mediated regulation of the cell: Introducing microRNA pharmacogenomics.
• Parenteral methotrexate in psoriasis. A report on the efficacy and toxicity of long-term intermittent treatment.
• Pharmacodynamics of Uniform versus Nonuniform Warfarin Dosages.
• Preclinical studies with triazinate (NSC-139105), an antifolate drug, in beagle dogs and rhesus monkeys.
• Protection of bone marrow cells from toxicity of chemotherapeutic agents targeted toward thymidylate synthase by transfer of mutant forms of human thymidylate synthase cDNA.
• Recent developments in chemotherapy of malignancy.
• Short-term sequential therapy with vinblastine (NSC-49842) and cyclophosphamide (NSC-26271) in Hodgkin's disease.
• The journal of clinical oncology: the initial years.
• Treatment of advanced neoplastic disease with 1-(2-chlorethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037).
• [Not Available.]